1. AB0294 Treatment modes in rheumatoid arthritis: factors influencing patient preference. (12th June 2018) Authors: Taylor, P.C.; Betteridge, N.; Brown, T.M.; Woolcott, J.; Kivitz, A.J.; Zerbini, C.; Whalley, D.; Olayinka-Amao, O.; Chen, C.; Dahl, P.; Ponce de Leon, D.; Gruben, D.; Fallon, L. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 1325 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. AB0460 Long-term drug survival of etanercept vs other tnf inhibitor therapies in patients with rheumatoid arthritis. (12th June 2018) Authors: Emery, P.; Vlahos, B.; Szczypa, P.; Thakur, M.; Jones, H.E.; Woolcott, J.; Santos Estrella, P.V.; Gibofsky, A.; Rolland, C.; Citera, G.; Marshall, L. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 1391 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. AB0827 IMPACT OF BASELINE BODY MASS INDEX ON THE EFFICACY AND SAFETY OF TOFACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS. (2nd June 2020) Authors: Ritchlin, C. T.; Ogdie, A.; Giles, J. T.; Gomez-Reino, J. J.; Helliwell, P.; Stockert, L.; Young, P.; Joseph, W.; Mundayat, R.; Graham, D.; Woolcott, J.; Romero, A. B. Journal: Annals of the rheumatic diseases Issue: Volume 79(2020)Supplement 1 Page Start: 1717 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. FRI0335 THE EFFECT OF TOFACITINIB ON RESIDUAL PAIN IN PATIENTS WITH PSORIATIC ARTHRITIS. (2nd June 2020) Authors: Dougados, M.; Van der Heijde, D.; Bingham, C.; Taylor, P. C.; Fallon, L.; Woolcott, J.; Brault, Y.; Wang, L.; Kessouri, M. Journal: Annals of the rheumatic diseases Issue: Volume 79(2020)Supplement 1 Page Start: 760 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. SAT0217 Identification of distinct disease activity trajectories in patients with rheumatoid arthritis receiving tofacitinib over 12 months. (12th June 2018) Authors: Bykerk, V. P.; van Vollenhoven, R.; Connell, C.; Gruben, D.; Fallon, L.; Woolcott, J.; Keystone, E. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 969 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. THU0169 Persistence of Tofacitinib in The Treatment of Rheumatoid Arthritis in Open-Label, Long-Term Extension Studies up To 7 Years. (15th July 2016) Authors: Pope, J.; Keystone, E.; Jamal, S.; Wang, L.; Fallon, L.; Woolcott, J.; Lazariciu, I.; Haraoui, B. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 245 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. THU0588 Reduction in the utilisation of prednisone and/or methotrexate following the initiation of etanercept in paediatric patients. (12th June 2018) Authors: Khraishi, M.; Millson, B.; Woolcott, J.; Jones, H.; Marshall, L. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 494 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗